LUMC/Centre for Human Drug Research
Leiden, Netherlands
NCT Number: NCT03071679
This study has a randomized, evaluator-blinded, vehicle- controlled study to assess the pharmacodynamics of omiganan and omiganan with imiquimod in healthy volunteers.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Leiden, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Omignan 1%, 2.5%
Imiquimod 15mg
Omiganan 1% and Imiquimod
Omiganan 2.5% and Imiquimod
Vehicle
Time frame: 6 Days
Erythema grading scale
Time frame: Within 2 Weeks
Local biomarker sequencing
Time frame: Within 2 Weeks
Histological parameters assessment
Time frame: Within 2 Weeks
Identification of lymphocytes and lineage cells
Time frame: Within 6 Days
Qualitatively and Quantitatively analyze biomarkers captured by Trans Epidermal Patch (TAP)
Time frame: Within 6 Days
Assess cutaneous microcirculation using laster speckle imager
Time frame: Within 6 Days
Colorimetric assessment by erythema grading scale
Time frame: Within 2 Weeks
Photographs of treatment sites will be taken
Time frame: Within 2 Weeks
Skin temperature measurements will be taken
Time frame: 2 Weeks
Visual Analogue Scale (NRS) pruritus and pain
Time frame: 2 Weeks
Adverse Events will be collected throughout the study
Time frame: 2 Weeks
Vital Signs will be collected throughout the study
Time frame: 2 Weeks
Lab samples collected in various timepoints within the study
Time frame: Within 3 Weeks
ECGs will be collected before beginning and end of study
Maruho Co., Ltd.
Industry
A Randomized, Evaluator-blinded, Vehicle-controlled Study to Explore the Pharmacodynamic Effects of Omiganan and Omiganan in Combination With Imiquimod in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details